PONY(300887)2025-01-17 11:28Financial Performance - The company expects a net loss for the fiscal year 2024, with an estimated loss between 33 million and 38 million yuan, compared to a profit of 10.778 million yuan in the same period last year, representing a decline of 406.18% to 452.57%[3] - The expected loss for net profit after deducting non-recurring gains and losses is estimated to be between 34.6 million and 39.6 million yuan, down 511.81% to 571.32% from a profit of 8.402 million yuan last year[3] - The basic earnings per share is projected to be a loss of 0.6045 yuan to 0.6960 yuan, compared to a profit of 0.1974 yuan per share in the previous year[3] Impairment Losses - The company has incurred approximately 93 million yuan in credit impairment losses related to accounts receivable and other receivables during the reporting period[5] - An additional 26 million yuan in asset impairment losses was recognized based on the impairment testing of long-term assets[5] - Non-recurring gains and losses are expected to impact the net profit attributable to shareholders by approximately 16 million yuan, compared to 23.77 million yuan in the same period last year[5] Investments and Costs - The company has made significant investments in the biopharmaceutical, new energy vehicle, and special industry testing sectors, which have led to high levels of costs and expenses during the reporting period[5] - The company is focusing on cost reduction and efficiency improvement measures to enhance operational efficiency and management levels[5] Operational Capacity - Several self-owned laboratories, including those in Shandong, Zhengzhou, Northwest, and Shanghai, are gradually being put into operation, which has affected the release of laboratory capacity[5] Financial Reporting - The financial data presented is preliminary and has not been audited, with detailed financial information to be disclosed in the 2024 annual report[6]